Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

• Published in: Clinical pharmacology in drug development Vol. 12; no. 2; pp. 202 - 211
• Main Authors: Parmar, Deven V., Kansagra, Kevinkumar A., Momin, Taufik, Patel, Hardik B., Jansari, Gaurav A., Bhavsar, Jay, Shah, Chintan, Patel, Jayesh M., Ghoghari, Ashok, Barot, Ajay, Sharma, Bhavesh, Viswanathan, Kasinath, Patel, Harilal V., Jain, Mukul R.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2023; John Wiley and Sons Inc
• Subjects: Area Under Curve; Drug dosages; healthy subjects; Humans; Inflammasomes - metabolism; Inhibitor drugs; Interleukin-18 - metabolism; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; NLRP3 inflammasome inhibitor; Original; pharmacodynamic; Pharmacodynamics; pharmacokinetic; Pharmacokinetics; safety; ZYIL1; ZYIL1; pharmacodynamic; pharmacokinetic; healthy subjects; safety; NLRP3 inflammasome inhibitor

ZYIL1 is a nucleotide‐binding oligomerization domain, leucine rich repeat and pyrin domain‐containing 3 (NLRP3) inflammasome inhibitor, which prevents NLRP3‐induced apoptosis‐associated speck‐like protein containing a caspase activation and recruitment domain oligomerization, thus inhibiting NLRP3 i...